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Background: This study investigated the association between innate immune reaction and myocardial damage
after acute myocardial infarction (AMI) and anti-inflammatory role of tacrolimus in reducing infarct size. Male mini-pigs
(n=18) were equally categorized into sham control (SC), untreated AMI (by ligation of left anterior descending
coronary artery), and AMI-Tacrolimus (AMI-Tac) (0.5 mg intra-coronary injection 30 minutes post-AMI). Cardiac
magnetic resonance imaging (MRI) was performed at post-AMI days 2, 5 and 21 before sacrificing the animals.
Results: By post-AMI day 21, left ventricular ejection fraction (LVEF) was lowest in untreated AMI animals, significantly
higher in SC than in AMI-Tac group (all p<0.003). Infarct areas at basal, middle, and apical levels, numbers of CD14+
and iNOS+ cells in infarct area (IA) and peri-IA, and protein expression of CD14, CD68, and Ly6g from circulating
inflammatory cells showed an opposite pattern compared with that of LVEF in all groups (all p<0.005). Protein
expressions of MCP-1, MIP-1, TNF-α, NF-κB, iNOS, and IL-12 in IA and peri-IA exhibited an identical pattern compared to
that of CD14, CD68, and Ly6g from circulating inflammatory cells (all p<0.01). Expressions of myocardial damage
biomarkers in IA and peri-IA [γ-H2AX, β-myosin heavy chain (MHC), Smad3, TGF-β] were highest in AMI and higher in
AMI-Tac than in SC, whereas expressions of myocardial integrity biomarkers (connexin43, mitochondrial cytochrome-C,
α-MHC, BMP-2, Smad1/5) were opposite to those of damage biomarkers (all p<0.001).
Conclusion: Innate immune responses were markedly augmented and LVEF was significantly reduced after AMI but
were remarkably improved after tacrolimus treatment.Background
Acute myocardial infarction (AMI) is the leading cause
of death worldwide [1-3]. The principal reason for poor
clinical outcomes after AMI is mainly due to left ven-
tricular (LV) remodeling following AMI that results in
LV dilatation and pump failure [4-7]. Since the essential
etiology of pump failure is closely related to the severity
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reproduction in any medium, provided the orfirst priority in the management of AMI is effective alle-
viation of myocardial damage and salvage of jeopardized
myocardium after AMI.
Despite prompt reperfusion [i.e., primary percutaneous
coronary intervention (PCI) or thrombolytic therapy] is
the current golden standard in the treatment of AMI
[10-12], unsuccessful reperfusion, including failure in re-
suming patency of the infarct artery through thromboly-
sis or slow-flow/no reflow after primary PCI [12-14],
remains the Achilles’ heel leading to unfavorable clinical
outcome [10,12,13]. The underlying mechanisms in-
volved in slow or no-reflow phenomenon have been ex-
tensively investigated [12,14,15]. Previous reports have
shown that high-burden thrombosis formation and
plaque content as well as ischemia-reperfusion injuryd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[12,14-17]. Additionally, IRI has been further demon-
strated to play the key role for propagation of myocardium
damage even after successful reperfusion. Moreover, the
phenomenon of IRI has also been identified to be essential
for up-regulating inflammatory response [14,18-20]. Of
particular importance is that the role of inflammation has
been highlighted by numerous recent studies as a critical
contributor to unsuccessful reperfusion, myocardial dam-
age and death after AMI [19,21-25]. Therefore, early in-
hibition of propagation of inflammatory reaction other
than reperfusion therapy may be also an important thera-
peutic strategy against progression of AMI-induced myo-
cardial damage which in turn, causes the LV dysfunction
and remodeling.
It is well-known that innate and adaptive immune sys-
tems are the two major defenses of the host against
micro-bacterial, viral, or other antigenic stimulations. In
contrast to the adaptive immune system that would need
time to act against the antigen (i.e., from memory to
immune cell differentiation and maturation), the non-
specific innate immune reaction always take quickly re-
sponse to the inflammatory or antigen-related stimulation.
Since AMI elicits prompt tissue necrosis and inflamma-
tion, it is conceivable that innate immunity has an import-
ant role to play a rapidly immune-inflammatory response,
especially at the early phase of AMI. Surprisingly, while
the link between AMI and inflammatory reaction has been
investigated in depth [21-27], the involvement of the in-
nate immune system in inflammation after AMI has only
been seldom reported [25,27].
Calcineurin, which possesses serine/threonine phos-
phatase activity, binds to nuclear factor of activated T
cells (NF-AT) which is then dephosphorylated and trans-
located to the nucleus for activating gene expression
of cytokines [28]. Tacrolimus, also named FK506, is a
macrolide immunosuppressant acting via lymphokine
signal transduction pathway [29]. Tacrolimus forms
the FK506-binding protein (FK-BP) (i.e., immunophilin
FKBP12) in cytoplasmic receptor which inactivates cal-
cineurin which is a central phosphatase for T cell signal-
ing [29,30]. Our recent experimental studies [26,27] have
revealed that tacrolimus treatment effectively attenuated
inflammation and MAPK signaling, limited infarct size,
and preserved LV function. However, our study did not
further investigate the potentially important role of in-
nate immunity after AMI, and the LV ejection fraction
(LVEF) was only measured by M-mode echocardiog-
raphy that would under- or over-estimate heart function.
Accordingly, the present study, using a mini-pig AMI
model, attempted to assess AMI-elicited activations of
innate immune signaling and particularly to determine
the role of tacrolimus in inhibiting inflammation and
preserving myocardial integrity as well as to evaluate LVfunction after AMI using a more accurate tool of cardiac
magnetic resonance imaging (MRI).
Methods
Ethics
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at
Chang Gung Memorial Hospital – Kaohsiung Medical
Center (Affidavit of Approval of Animal Use Protocol
No. 2008121108) and performed in accordance with
the Guide for the Care and Use of Laboratory Animals
(NIH publication No. 85–23, National Academy Press,
Washington, DC, USA, revised 1996). The IRB number
of this animal study was 2011070502.
Mini-Pig AMI model
The procedure and protocol of the animal model of
AMI and the rationale of drug dosage were based
on our recent report [26]. Briefly, each male mini-pig
(Taitung Animal Propagation Station, Livestock Research
Institute, Taiwan), weighing 16–18 kg, was anesthetized
by intramuscular injection of ketamine (15 mg/kg) and
maintained in anesthetized condition using an inhalation
of 1.5% isoflurane for the whole procedure. After being
shaved on the chest, the mini-pig was placed in supine
position on a warming pad at 37°C and then received
endotracheal intubation with positive-pressure ventila-
tion (180 mL/min) with room air using a ventilator (Sn:
Q422ZO, SIMS PneuPAC, Ltd.) during the procedure.
Electrocardiogram (ECG) monitor and defibrillator were
connected to the chest wall of each mini-pig. One am-
poule of amiodarone (150 mg) was intravenously given
to each animal before the AMI-induction procedure to
prevent the occurrence of malignant arrhythmia.
Under sterile conditions, the heart was exposed through
mid-thoracotomy. The pericardium was gently removed
and the mid-portion of left anterior descending (LAD) ar-
tery was ligated with 5–0 prolene suture just distal to the
first diagonal branch. Regional myocardial ischemia is
confirmed by typical changes in waveform on ECG moni-
tor and the observation of rapid discoloration of myocar-
dium from pink to gray over the anterior surface of left
ventricle, together with the rapid development of akinesia
and dilatation of at-risk area. AMI was confirmed by
complete ECG following the procedure. After mid-LAD li-
gations, the mini-pigs were then categorized into AMI
plus normal saline treatment (AMI-only) group (n=6) and
AMI plus tacrolimus therapy (AMI-Tac) group (n=6). For
the purpose of comparison at molecular-cellular levels,
normal cardiac tissues were obtained from a group of six
mini-pigs without receiving any treatment that served as
the normal controls (NC).
The optimal drug dosage of tacrolimus has been dem-
onstrated in our recent study to be 0.5 mg to achieve
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dosage of tacrolimus (i.e., 0.5 mg for each animal) was
utilized in the current study. By 30 minutes after LAD
ligation, intra-coronary injections of physiological saline
(3.0 mL) in AMI-only group and tacrolimus (0.5 mg in
2.5 mL physiological saline) in AMI-Tac group were
given through the LAD beyond the point of ligation.
The muscle and skin of the chest wall were then closed
in layers. The animals were allowed to recover on the
warming pad under close observation.
Cardiovascular magnetic resonance imaging (MRI)
analysis on days 2, 5 and 21 after AMI induction
The MRI protocol and procedure were according to our
recent report [31]. Briefly, all animals in AMI group and
AMI-Tac group underwent cardiovascular MRI studies
on day 2, 5 and 21 after LAD ligation. All studies were
performed by one investigator (with 15 years of experi-
ence in chest and cardiovascular MRIs) blinded to the
treatment protocol using a 1.5T MR imager (Intera;
Philips Medical Systems, Best, the Netherlands). After
anesthesia, the mini pig was placed in a supine position
with all four limbs fixed by Velcro strips. A phased array
coil was wrapped around the chest. A cine MRI for as-
sessment of LV volume and function was performed
using a balanced steady-state free precession sequence
with the following parameters: Repetition time msec/
echo time msec, 3.7/1.8; section thickness, 10 mm; spa-
cing, 0; flip angle, 70°; field of view, 26 × 26 cm; matrix
size, 239 × 256; number of signals acquired, one; and,
number of phases, 25. To measure the late gadolinium
enhancement (LGE) MR imaging of the infarct area, 0.2
mmol/kg body weight (BW) gadopentetate dimeglumine
(Magnevist, Bayer Schering Pharma, Berlin, Germany)
was administered at 0.6 mL/s via the ear vein with a
power injector (Spectris; Medrad, Indianola, PA) followed
by a 5 mL saline flush. Twelve minutes post contrast
injection, a 2D gradient-recalled-echo technique with
gating & inversion recovery preparation was applied
for late gadolinium enhancement (LGE) study with the
inversion time (approximately 300–380 milliseconds)
being optimized by myocardial nulling. LV functional
parameters were determined by segmentation of the
endocardial and epicardial contours of each slice dur-
ing end-systole (ES) and end-diastole (ED) allowing for
the evaluation of ED volume, ES volume, and ejection
fraction (EF).
The mini pigs were sacrificed on day 21 after AMI in-
duction for individual study. For the comparison of
molecular-cellular biomarker changes among animals in
the normal control, AMI without treatment, and AMI
treated with tacrolimus groups, LV tissues from six other
normal animals were utilized. These six animals did not
receive cardiac MRI examination.Specimen collection, measurement of infarct area at
basal, middle, and apical level of left ventricle
By day 21 after cardiac MRI examination, the twelve
mini-pigs were sacrificed and the hearts were rapidly re-
moved and immersed in cold saline and prepared for in-
dividual study. For immunohistofluorescence (IF) study,
the heart tissue was rinsed with PBS, embedded in OCT
compound (Tissue-Tek, Sakura, Netherlands) and snap-
frozen in liquid nitrogen. Some heart tissue was also
stored at −80°C for Western blot. For immunohistochemi-
cal (IHC) staining, heart tissue was fixed in 4% formalde-
hyde and embedded in paraffin.
Three cross-sections (1 cm in thickness) of the re-
moved heart were obtained at identical basal, middle,
and apical levels in each animal for measurement of
myocardial infarct size in both placebo and cell-treated
groups. To avoid the possibility of bias, the technicians
who assessed the infarct area at basal, middle and apical
levels were blinded to the therapeutic strategy. Each
cross-section of heart tissue was then stained with tri-
methyl tetrazolium chloride (2% TTC) for infarct area
analysis. Briefly, all heart sections were placed on a tray
with a scaled vertical bar to which a digital camera was
attached. The sections were photographed from directly
above at a fixed height. The images obtained were then
analyzed using Image Tool 3 (IT3) image analysis soft-
ware (University of Texas, Health Science Center, San
Antonio, UTHSCSA; Image Tool for Windows, Version
3.0, USA). The calculated infarct area (i.e., the average
infarct area) was expressed as the percentage of infarct
area (IA) compared with the total cross-sectional area of
the left ventricle in each section for comparison [i.e. IA /
(IA + non-IA) × 100%]. The rest of the cardiac tissue
was then cut into pieces for specific studies.
For other molecular-cellular biological studies, the
specimen of peri-IA was collected. To avoid incorrect
tissue samplings of the peri-IA that would influence the
outcome, the specimen of peri-IA (i.e., an area-at-risk)
was collected at least 5 mm away from the edge of the
infarct area.
The technicians/observers who performed imaging or
molecular-cellular biological studies were blinded to the
treatment protocol.
Western blot analysis of left ventricular specimens
Equal amounts (30 μg) of protein extracts from the left
ventricular myocardium were loaded and separated by
SDS-PAGE using 8-10% acrylamide gradients. The
membranes were incubated with the indicated primary
antibodies against CD14 (1:1000, Abcam), CD68 (1:500,
Abcam), Ly6G (1:1000, Abcam), connexin43 (Cx43)
(1:1000, Chemicon), mitochondrial cytochrome C (1:2000,
BD), tumor necrosis factor (TNF)-α (1: 1000, Cell Signaling),
nuclear factor (NF)-κB (1:600, Abcam), interleukin (IL)-12
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(MCP)-1 (1:500, Abcam), macrophage inflammatory
protein (MIP)-1α (1:2000, Abcam), inducible nitric oxide
synthase (iNOS) (1:250, Abcam), and γH2AX (1:1000, Cell
signaling). Signals were detected with horseradish per-
oxidase (HRP)-conjugated goat anti-mouse, goat anti-
rat, or goat anti-rabbit IgG.
Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences), which
was then exposed to Biomax L film (Kodak). For quantifi-
cation, ECL signals were digitized using Labwork software
(UVP). For oxyblot protein analysis, a standard control
was loaded on each gel.
Immunohistochemical (IHC) staining
The procedure was based on our recent reports [25-27,32].
Briefly, paraffin sections (3 μm thick) were obtained from
LV myocardium of each mini-pig. To block the action of
endogenous peroxidase, the sections were initially incu-
bated with 3% hydrogen peroxide, and then further proc-
essed using Beat Blocker Kit (Zymed Company, #50-300)
with immersion in solutions A and B for 30 minutes and
10 minutes, respectively, at room temperature. Primary
antibodies against CD14 (dilution 1/500; Spring Bioscience)
and iNOS (dilution 1/200; Spring Bioscience) were then
used, followed by application of SuperPicTureTM Poly-
mer Detection Kit (Zymed) for 10 minutes at room
temperature. Finally, the sections were counterstained
with hematoxylin. For negative control experiments,
primary antibodies were omitted.
Immunofluorescent (IF) imaging study
IF staining methodology for identification of phos-
phorylated variants of histone H2AX (γ-H2AX) in
myocardium was utilized according to our recent re-
ports [25-27,32]. The primary antibody [anti-γ-H2AX
(Abcam)] and secondary antibody [Alex594-conjugated
anti-mouse IgG (Molecular Probes)] were incubated
for 30 minutes at room temperature. Irrelevant anti-
bodies were used as control.
Immunolabeling of connexin43 (Cx43) and quantitative
image data analysis
Six serial sections of LV myocardium (three longitudinal
and three transverse) were prepared at 4 μm thickness
by Cryostat (Leica CM3050S) for Cx43 immunolabeling.
To co-localize troponin I and Cx43 in the same sample,
tissue sections were first incubated with a mixture of
polyclonal anti-Cx43 (1:200) plus anti-troponin I (1:200)
antibodies for 24 h at 4°C then incubated with anti-
mouse FITC (1:200) and anti-rabbit Rhodamine (1:200)
for 30 minutes at room temperature.
The integrated area (μm2) of Cx43 spots in the tissue
sections was calculated using Image Tool 3 (IT3) imageanalysis software (University of Texas, Health Science Cen-
ter, San Antonio, UTHSCSA; Image Tool for Windows,
Version 3.0, USA) as described previously [25-27,32].
Three selected sections were quantified for each animal.
Three randomly selected high-power fields (HPFs) (400 x)
were analyzed in each section. After determining the
number of pixels in each Cx43 spot per HPF, the numbers
of pixels obtained from the three HPFs were summated.
The procedure was repeated in two other sections for
each animal. The mean pixel number per HPF for each
animal was then determined by summating all pixel
numbers and dividing by 9. The mean area of Cx43
per HPF was obtained using a conversion factor of
19.24 (1 μm2 represented 19.24 pixels).
Statistical analysis
Quantitative data are expressed as means ± SD. Statistical
analysis was adequately performed by ANOVA followed by
Bonferroni multiple-comparison post hoc test. Statistical
analysis was performed using SAS statistical software for
Windows version 8.2 (SAS institute, Cary, NC). A probabil-
ity value <0.05 was considered statistically significant.
Results
Time courses of cardiac MRI findings after AMI induction
The ratio (R) of end-diastolic volume (EDV) to the body
weight (BW) (REDV/BW) (ml/kg) did not differ between
AMI group and AMI-Tac group at day 2 and day 5 after
AMI induction (Figure 1A). However, the REDV/BW was
significantly higher in AMI group than in AMI-Tac
group by day 21 after AMI induction. Additionally, the
ratio of end-systolic volume (ESV) to BW (RESV/BW) was
similar between the AMI group and AMI-Tac group by
day 2 after AMI induction. However, this parameter was
significantly higher in AMI group than in AMI-Tac group
by day 5 and day 21 after AMI induction (Figure 1B).
These findings suggest that tacrolimus therapy signifi-
cantly inhibited LV remodeling after AMI.
The LVEF did not differ between the AMI group and
AMI-Tac group by day 2 after AMI induction. However,
the LVEF was significantly lower in AMI group than that
in AMI-Tac group by day 5 (Figure 1C). Moreover, by
day 21, this parameter was significantly lower in the
AMI group compared with that in AMI-Tac group.
These findings imply that tacrolimus therapy signifi-
cantly improved LV function after AMI.
The stroke volume did not differ between the AMI group
and AMI-Tac group by days 2 and 5 after AMI induction
(Figure 1D). However, the stroke volume was significantly
increased in AMI-Tac group than in AMI group by day 21.
These findings suggest once more tacrolimus therapy sig-
nificantly preserved LV function after AMI.
The LGE of the infarct area was similar between the AMI
group and AMI-Tac group by day 2 after AMI induction.
Figure 1 Cardiac magnetic resonance imaging (MRI) findings. A) The ratio of end diastolic (ED) volume to body weight (BW) by days 2, 5
and 21 after acute myocardial infarction (AMI) induction. By day 21, * vs. †, p<0.005. B) The ratio of end systolic (ES) volume to BW by days 2, 5
and 21 after AMI induction. By day 5, * vs. †, p<0.01. By day 21, ‡ vs. §, p<0.01. C) Left ventricular (LV) ejection fraction by days 2, 5 and 21 after
AMI induction. By day 5, * vs. †, p<0.01. By day 21, ‡ vs. §, p<0.01. D) Stroke volume by days 2, 5 and 21 after AMI induction. By day 21, * vs. †,
p<0.01. E) % of enhanced area on late gadolinium enhancement (LGE) by days 2, 5 and 21 after AMI induction. By day 5, * vs. †, p<0.01. By day
21, ‡ vs. §, p<0.01. Tac = tacrolimus. (n=6 for each group).
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day 5 and more significantly reduced by day 21 in AMI-Tac
group than in AMI group. These findings implicate that
tacrolimus treatment significantly reduced tranasmural
infarct size and prevented myocardium from death.
Assessment the infarct area of LV myocardium and
thickness of LV wall
Figure 2 shows the results of TTC staining by day 21
following AMI. As expected, the IA was notably larger in
AMI group than that in AMI-Tac group at basal, middle,
and apical levels (Figure 2A). Accordingly, the quantifica-
tion of the IA showed significantly larger area of infarction
at all three levels in AMI group than that in AMI-Tac group
(Figure 2B). By contrast, summation of the wall thickness at
all three levels demonstrated significantly thinner LV wall
in the AMI group as compared with that in the AMI-Tac
group (Figure 2C). These findings may partially explain
the notably higher LVEF and remarkably reduced LV
remodeling in AMI animals with tacrolimus treatment
compared to those without.
Measurement of Innate immune response in the circulation
and in IA and peri-IA by Day 21 after AMI induction
The protein expressions of CD14 (extracted from
peripheral-blood mononuclear cells), CD68 (extractedfrom peripheral-blood macrophages), and Ly6G (extract
from circulating neutrophils), three indices of innate im-
mune response, were significantly higher in AMI group
than those in AMI-Tac group and normal controls (NC),
and significantly higher in AMI-Tac group than those in
NC (Figure 3).
IHC staining showed that the numbers of CD14+ cells
(Figure 4, upper panel) and inducible NO synthase (iNOS)+
(i.e., the innate immune signaling cascade) (Figure 4, lower
panel), two indicators of innate immune response, in both
IA and peri-IA were significantly higher in AMI group than
those in AMI-Tac group and NC, and significantly higher in
AMI-Tac group than those in NC.
Determination of protein expressions of innate
inflammatory reaction in IA and Peri-IA by day 21 after
AMI induction
The protein expressions of TNF-α, IL-12 (Figure 5),
MCP-1, MIP-1α, and iNOS (Figure 6), six indices of in-
nate inflammatory response in IA and peri-IA, were sig-
nificantly higher in AMI group than those in AMI-Tac
group and NC, and significantly higher in AMI-Tac group
than those in NC. Additionally, the ratio of phosphorylated-
NF-κB/total NF-κB was significantly higher in AMI group
than in AMI-Tac group and NC, but it showed no differ-
ence between AMI-Tac group and NC.
Figure 2 Histopathological findings of infarct area by day 21 after AMI. A) Illustrations of trimethyl tetrazolium chloride (TTC) staining of the
left ventricular (LV) infarct area at basal, middle and apical areas by day 21 after AMI induction. B) Statistical analysis showed significantly lower
infarct area at basal, middle and apical levels of left ventricle in AMI + Tac group than in AMI group (all p values <0.05). C) Quantification of wall
thickness in infarct area. * vs. †, p<0.05. Tac = tacrolimus. (n=6 for each group).
Sheu et al. Journal of Biomedical Science 2013, 20:82 Page 6 of 14
http://www.jbiomedsci.com/content/20/1/82Immunofluorescent microscopic findings of myocardial
integrity biomarkers in peri-IA and non-IA by day 21 after
AMI induction
IF staining demonstrated that the number of γ-H2AX+
cells, an index of DNA damage in peri-IA and non-IA,
was significantly higher in AMI group than that in
AMI-Tac group and NC, and significantly higher inFigure 3 Protein extraction of innate immune cells in the circulation by d
peripheral-blood mononuclear cells. * vs. other bars with different symbols, p<0
macrophages. * vs. other bars with different symbols, p<0.005. C) Protein expres
different symbols, p<0.001. All statistical analyses using one-way ANOVA, followe
indicate significance (at 0.05 level). NC = normal control. AMI = acute myocardiaAMI-Tac group than that in NC (Figure 7). On the
other hand, IF also revealed that the Cx43-expression
area, an indicator of integrity of gap junction between
cardiomyocytes in peri-IA and non-IA, was signifi-
cantly reduced in AMI group than in AMI-Tac group
and NC, and significantly reduced in AMI-Tac group
than that in NC (Figure 8). These findings support thatay 21 after AMI induction. A) Protein expression of CD14 extracted from
.005. B) Protein expression of CD68 extracted from peripheral-blood
sion of Ly6G extract from circulating neutrophils. * vs. other bars with
d by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡)
l infarction; Tac = tacrolimus. (n=6 for each group).
Figure 4 Immunohistochemical (IHC) staining of the innate inflammatory cells in infarct area (IA) and peri-IA at day 21 after AMI
induction. Upper panel: A to E) Illustration of IHC staining of CD14+ cells (yellow arrows) in infarct area (IA) and peri-IA of left ventricle. F)
Quantification of number of CD14+ cells. At IA, * vs. other bars with different symbols, p<0.0001. At peri-IA, * vs. other bars with different
symbols, p<0.01. (n=6 for each group). Lower panel: A to E) Illustration of IHC staining of inducible nitric oxide synthase (iNOS) + cells (yellow
arrows) in IA and peri-IA of left ventricle. F) Quantification of iNOS+ cells. At IA, * vs. other bars with different symbols, p<0.0001. At peri-IA,
* vs. other bars with different symbols, p<0.001. All statistical analyses using one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test. Symbols (*, †, ‡ or *, §, ¶) indicate significance (at 0.05 level). HPF = high-power field; AMI = acute myocardial infarction;
Tac = tacrolimus. (n=6 for each group).
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Figure 5 Protein expressions of innate inflammatory
biomarkers of TNF-α, NF-κB, and IL-12 by day 21 after AMI
induction. A) The protein expressions tumor necrotic factor (TNF)-α
in infarct area (IA). * vs. other bars with different symbols, p<0.001.
B) The protein expression of TNF-α in per-IA. * vs. other bars with
different symbols, p<0.01. C) The ratio of protein expression of
phosphorylated (p) nuclear factor (NF)-κB/total NF-κB in IA. * vs.
other bars with different symbols, p<0.01. D) The ratio of protein
expression of p-NF-κB/total NF-κB in peri-IA. * vs. other bars with
different symbols, p<0.05. E) Protein expression of interleukin (IL)-12
in IA. * vs. other bars with different symbols, p<0.001. F) Protein
expression of IL-12 in peri-IA. * vs. other bars with different symbols,
p<0.0001. All statistical analyses using one-way ANOVA, followed by
Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡)
indicate significance (at 0.05 level). NC = normal control; AMI =
acute myocardial infarction; Tac = tacrolimus. (n=6 for each group).
Figure 6 Protein expressions of innate inflammatory
biomarkers of MCP-1, MIP-1, and iNOS by day 21 after AMI
induction. A) The protein expressions monocyte chemoattractant
protein (MCP)-1 in infarct area (IA). * vs. other bars with different
symbols, p<0.01. B) The protein expression of MCP-1 in peri-IA. * vs.
other bars with different symbols, p<0.01. C) The protein expression
of macrophage inflammatory protein (MIP)-1 in IA. * vs. other bars
with different symbols, p<0.01. D) The protein expression of MIP-1 in
peri-IA. * vs. other bars with different symbols, p<0.01. E) The
protein expression of inducible nitric oxide synthase (iNOS) in IA. *
vs. other bars with different symbols, p<0.01. F) The protein
expression of iNOS in peri-IA. * vs. other bars with different symbols,
p<0.01. All statistical analyses using one-way ANOVA, followed by
Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡)
indicate significance (at 0.05 level). NC = normal control; AMI =
acute myocardial infarction; Tac = tacrolimus. (n=6 for each group).
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Figure 7 Immunofluoroscopic findings of γ-H2AX+ cells in peri-infarct area (IA) and non-IA by day 21 after AMI induction. A to E) The
illustration of immunofluorescent (IF) stain of γ-H2AX+ cells in peri-IA and non-IA. F) Quantification of number of γ-H2AX+ cells in peri-IA and
non-IA. At peri-IA, * vs. other bars with different symbols, p<0.0001. At non-IA, * vs. other bars with different symbols, p<0.001. All statistical
analyses using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡ or *, §, ¶) indicate significance (at 0.05
level). HPF = high-power field; NC = normal control; AMI = acute myocardial infarction; Tac = tacrolimus. (n=6 for each group).
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damaged after AMI induction.
Examination of protein expressions of myocardial integrity
biomarkers in IA and peri-IA by day 21 after AMI induction
The protein expression of mitochondrial cytochrome-C,
and index of mitochondrial integrity and energy preser-
vation in IA and peri-IA, was significantly lower in the
untreated AMI group than that in AMI-Tac group and
NC, and significantly lower in AMI-Tac group than that
in NC in IA, but it showed no difference between the lat-
ter two groups in peri-IA (Figure 9A and B). Addition-
ally, the protein expression of Cx43 in IA and peri-IA
was significantly lower in AMI group than that in AMI-
Tac group and NC, and significantly lower in AMI-Tac
group than that in NC (Figure 9C and D). However, the
protein expression of γ-H2AX in IA and peri-IA showed
an opposite pattern compared to that of Cx43 among
the three groups (Figure 9E and F).
The protein expressions of TGF-β and Smad3, two fi-
brotic biomarkers in IA and peri-IA, were significantly
higher in animals with untreated AMI than that in the
AMI-Tac group and NC, and significantly higher in the
AMI-Tac group than that in NC (Figure 10A to D). Con-
versely, the protein expressions of BMP-2 and Smad1/5,
two anti-fibrotic indices in IA and peri-IA, showed anopposite pattern compared to that of fibrotic biomarkers
in the three groups (Figure 10E to H).
Discussion
This study, which investigated the role of innate immune
response and the impact of tacrolimus therapy in mini-pig
AMI model, yielded several striking implications. First,
not only was the innate immune system in circulation
enhanced in circulation after AMI induction, but it was
also significantly activated in the myocardium. Second,
the expressions of myocardial damage biomarkers were
markedly augmented, whereas those of myocardial in-
tegrity were remarkably reduced after AMI. Third, myo-
cardial IA and LV remodeling were notably suppressed,
whereas the LVEF was significantly preserved after ta-
crolimus therapy. Accordingly, the results of this study
highlight the therapeutic potential of tacrolimus in the
setting of AMI.
Distinctive therapeutic potential of tacrolimus against
AMI --- changes in IA and cardiac MRI assessment of LV
function and remodelling
The most important finding in the present study is the
remarkable preservation of LVEF after AMI induction in
animals with tacrolimus treatment compared to those
without. Moreover, another distinctive finding in the
Figure 8 Immunofluoroscopic findings of connexin43 expression in peri-infarct area (IA) and non-IA by day 21 after AMI. A to E) The
illustration of immunofluorescent (IF) stain of connexin43 (Cx43) expression in peri-IA and non-IA. F) Quantification of CX43 distribution (area) in
per-IA and non-IA. At peri-IA, * vs. other bars with different symbols, p<0.0001. At non-IA, * vs. other bars with different symbols, p<0.001. All
statistical analyses using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡ or *, §, ¶) indicate
significance (at 0.05 level). HPF = high-power field; AMI = acute myocardial infarction; Tac = tacrolimus. (n=6 for each group).
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modeling after tacrolimus treatment.
The pathological findings of myocardial infarction after
LAD ligation confirmed the successful establishment of
the animal model. Histologically, IA at apical, middle, and
basal levels of left ventricle was markedly increased after
induction of myocardial infarction but was substantially
reduced following tacrolimus treatment. Fascinatingly,
although it is conceivable that the low tacrolimus dos-
age for local cardiac administration probably caused a
very low circulating drug level compared to its use as
immunosuppressant, it remarkably reduced infarct size,
suppressed LV remodeling, and preserved cardiac func-
tion. Such distinct advantage highlights the therapeutic
potential of tacrolimus as a safe and efficient cardiac
protective agent, instead of its routine use as a systemic
immunosuppressant.
Undoubtedly, cardiac MRI is more accurately than
M-mode echocardiography for measuring the left ven-
tricular function, especially after AMI. Using echocardi-
ography, our previous study showed that as compared to
AMI group, AMI + tacrolimus significantly improved
LVEF and attenuated LV chamber size by day 14 after
AMI induction [26]. In the present study, we utilized
cardiac MRI to measure the serial changes of LVEF,stroke volume and LV dimension and the results ex-
hibited that tacrolimus therapy significantly improved
heart function and inhibited LV remodeling. In this
way, the MRI findings of the present study support the
echocardiography findings of our previous study [26].
Of particularly important finding was that the cardiac
MRI rather than the echocardiography provided the
useful information of transmural LGE in the infarct
area that could accurately assess that percentage of the
infarct wall and the survival of myocardium after AMI
induction with and without tacrolimus therapy. In this
way, the cardiac MRI is superior to echocardiography
for identifying the myocardial integrity after AMI.
Circulating inflammatory reaction after AMI --- innate
immune signaling
Undoubtedly, AMI elicits tremendous local and systemic
inflammatory responses [21-25]. One important finding
in the present study was that the CD14, CD68, and
Ly6G, typical and critical cell expressing innate markers,
is the remarkably in circulation after AMI. This finding
supports that an augmented innate immune response
frequently occurs in the circulation after AMI. Our finding
not supports those from previous studies [21-25] but also
highlights that the innate immune system is throughout
Figure 9 Protein expressions of myocardial integrity biomarkers of
mitochondrial cytochrome C, connexin43 and γ-H2AX in infarct
area (IA) and peri-IA by day 21 after AMI induction. A) protein
expression of mitochondrial cytochrome C in IA. * vs. other bars with
different symbols, p<0.005. B) protein expression of mitochondrial
cytochrome C in peri-IA. * vs. other bars with different symbols,
p<0.01. C) protein expression of connexin43 (Cx43) in IA. * vs. other
bars with different symbols, p<0.01. D) protein expression of Cx43
in peri-IA. * vs. other bars with different symbols, p<0.01. E) Protein
expression of γ-H2AX in IA. * vs. other bars with different symbols,
p<0.001. F) Protein expression of γ-H2AX in peri-IA. * vs. other bars
with different symbols, p<0.001. All statistical analyses using
one-way ANOVA, followed by Bonferroni multiple comparison post
hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level). NC =
normal control; AMI = acute myocardial infarction; Tac = tacrolimus.
(n=6 for each group).
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markers of innate immunity were remarkably attenuated
after tacrolimus treatment. The possible mechanism
underlying the observation would be the inhibition ofmyocardial inflammatory reaction that, in turn, sup-
pressed the expression of inflammatory mediators in
the circulation.Local inflammatory reaction in myocardium after AMI --
innate immune signaling and myocardial damage
Propagation of inflammatory reaction has been well
recognized as a significant contributor to myocardial
damage after AMI [22-27]. However, the extent of in-
volvement of the innate immune system in regulating
the inflammatory reaction after AMI has not been fully
investigated [25,27]. An essential finding in the present
study is that not only the protein (i.e., TNF-α, NF-κB,
IL-12, MCP-1, MIP-1α, and iNOS), but also the cellular
(CD14+ and iNOS+ cells) expressions of innate immune
reactions were found to be involved in AMI-induced in-
flammatory process in myocardium. Thus, our findings
implicate that the inflammation and immune response is
actually the coin of both side, very close related to each
other after AMI induction. Additionally, our findings
once gain support that the innate immune system is
not only throughout activated in circulation but it also
entirely augmented in infarction area after AMI. More-
over, these findings, in addition to reinforcing those
from previous studies [22-27], could at least in part ex-
plain the aggravated pathological cardiac changes in
animals without treatment. Of particularly importance
is the finding of significantly reduced IA animals after
tacrolimus treatment. The results could partially ex-
plain the notably preserved LVEF and alleviated LV re-
modeling in the tacrolimus-treated animals.Effects of tacrolimus on myocardial damage and integrity
Previous studies have clearly demonstrated that the expres-
sions of myocardial damage and remodeling biomarkers
(i.e., TGF-β, Smad3, MHC-β, cytosolic cytochrome C)
were markedly enhanced after AMI [21,25-27,32]. By
contrast, the expressions of myocardial integrity bio-
markers (i.e., BMP-2, Smad1/5, Cx43, MHC-α, mito-
chondrial cytochrome C) were remarkably decreased
[21,25-27,32]. Of importance is that link between the
increased expressions of myocardial damage parameters
that stand for the propagation of inflammatory reac-
tions and the deterioration in cardiac function. In this
way, our findings are consistent with those of previous
studies [21,25-27,32]. One important finding in the
present study is that notably attenuated expressions of
myocardial damage biomarkers in AMI animals after
tacrolimus treatment. These findings again partially ex-
plain the preserved LVEF in tacrolimus-treated animals
after AMI. Our finding, therefore, not only explains the
remarkably suppressed LV remodeling after tacrolimus
treatment, but also supports the use of this agent as a
Figure 10 Protein expressions of fibrotic and anti-fibrotic markers in infarct area (IA) and peri-IA by day 21 after AMI. A) The protein
expression of transforming growth factor (TGF)-β in IA. * vs. other bars with different symbols, p<0.001. B) The protein expression of TGF-β in
peri-IA. * vs. other bars with different symbols, p<0.001. C) The protein expression of phosphorylated (p)-Smad3 in IA. * vs. other bars with
different symbols, p<0.01. D) The protein expression of p-Smad3 in peri-IA. * vs. other bars with different symbols, p<0.01. E) The protein
expression of bone morphogenic protein (BMP)-2 in IA. * vs. other bars with different symbols, p<0.001. F) The protein expression of BMP-2 in
peri-IA. * vs. other bars with different symbols, p<0.01. G) The protein expression of p-Smad1/5 in IA. * vs. other bars with different symbols,
p<0.001. H) The protein expression of p-Smad1/5 in peri-IA. * vs. other bars with different symbols, p<0.001. All statistical analyses using one-way
ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level). NC = normal control;
AMI = acute myocardial infarction; Tac = tacrolimus. (n=6 for each group).
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ing just received primary PCI.
Why we utilized the same animal model in three
consecutive studies to determining the therapeutic effect
of tacrolimus on STEMI?
The same animal model and identical strategic treat-
ment had been performed by our two previous studies
[26,27]. In our two previous studies [26,27], we have
measured the inflammatory and apoptotic biomark-
ers, the generations of oxidative stress and antioxi-
dants, and MAPK signaling pathway, respectively. In
the present study, we focused on assessing the innate
immune response. The results of the present study pro-
vided critical complementary information that associ-
ate with the data from our previous studies [26,27]
can, therefore, highlight a more completely history of
molecular-cellular perturbations, inflammatory reaction
and the immune response in setting of AMI, as well asthe potentially accessorily therapeutic impact of tacroli-
mus for STEMI patients in the near future.
Study limitations
This study has limitations. First, without examination of
adaptive immune system, the extent of participation of
this immune system in regulating the inflammatory
process after the occurrence of AMI remains to be eluci-
dated. Second, since the current study did not investi-
gate mitochondrial dysfunction [i.e., the opening of the
mitochondrial permeability-transition (MPT) pore after
AMI], whether heart function was preserved through
regulation of the MPT pore in damaged myocardium
after tacrolimus therapy in AMI animals is also unclear.
Third, the cardiac MRI measurement was done on days
2, 5 and 21 after AMI induction rather than the basal
values at day 0 prior to the induction of AMI on the
AMI and AMI + Tac groups. Thus, the acute effect of
AMI on cardiac functions did not provide from the
Figure 11 Proposed mechanisms underlying the effects of tacrolimus therapy on preservation of heart function in a min-pig AMI
model based on the findings of the present study. IF = immunofluorescent; IHC = immunohistochemical; Cx43 = connexin43; Mito-Cyt
C = mitochondrial cytochrome C; Cyto-Cyt C = cytosolic cytochrome C; LGE = late gadolinium enhancement; LV = left ventricular; ED = end
diastolic; ES = end stroke; BW = body weight.
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work had been done in the current study, the exactly
underlying mechanisms of the innate immunity has played
an important role in the pathogenesis of AMI is still not
entirely investigated and that the mechanistic basis in-
volved in the improvement of heart function after tacroli-
mus therapy has not been fully clarified. The proposed
mechanisms have been summarized in Figure 11 based on
our findings.
Conclusion
The innate immune system was significantly and exten-
sively upregulated after AMI in a swine model. Tacrolimustherapy effectively suppressed the inappropriate innate im-
mune response and LV remodeling, thereby significantly
preserving LVEF after AMI in this experimental setting.Competing interests
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